JP2013504590A - 非放射性リン脂質化合物、組成物、及び使用方法 - Google Patents

非放射性リン脂質化合物、組成物、及び使用方法 Download PDF

Info

Publication number
JP2013504590A
JP2013504590A JP2012528915A JP2012528915A JP2013504590A JP 2013504590 A JP2013504590 A JP 2013504590A JP 2012528915 A JP2012528915 A JP 2012528915A JP 2012528915 A JP2012528915 A JP 2012528915A JP 2013504590 A JP2013504590 A JP 2013504590A
Authority
JP
Japan
Prior art keywords
radioactive
cancer
group
iodine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504590A5 (enExample
Inventor
ピンチュク アナトリー
ロンギーノ マーク
ピー．ウェイチャート ジェイミー
アール．クラーク ウィリアム
エム．バッカロ アブラム
カンデラ イラワティ
Original Assignee
セレクター，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクター，インコーポレイティド filed Critical セレクター，インコーポレイティド
Publication of JP2013504590A publication Critical patent/JP2013504590A/ja
Publication of JP2013504590A5 publication Critical patent/JP2013504590A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012528915A 2009-09-11 2010-09-10 非放射性リン脂質化合物、組成物、及び使用方法 Pending JP2013504590A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24175909P 2009-09-11 2009-09-11
US24176209P 2009-09-11 2009-09-11
US61/241,762 2009-09-11
US61/241,759 2009-09-11
US30921310P 2010-03-01 2010-03-01
US30918710P 2010-03-01 2010-03-01
US61/309,187 2010-03-01
US61/309,213 2010-03-01
PCT/US2010/048351 WO2011031919A2 (en) 2009-09-11 2010-09-10 Non-radioactive phospholipid compounds, compositions, and methods of use

Publications (2)

Publication Number Publication Date
JP2013504590A true JP2013504590A (ja) 2013-02-07
JP2013504590A5 JP2013504590A5 (enExample) 2013-10-24

Family

ID=43730778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528915A Pending JP2013504590A (ja) 2009-09-11 2010-09-10 非放射性リン脂質化合物、組成物、及び使用方法

Country Status (5)

Country Link
US (2) US20110064661A1 (enExample)
EP (1) EP2475400A2 (enExample)
JP (1) JP2013504590A (enExample)
RU (1) RU2012114146A (enExample)
WO (1) WO2011031919A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535608A (ja) * 2014-11-17 2017-11-30 セレクター・バイオサイエンシズ・インコーポレイテッド 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
US12496346B2 (en) 2019-10-10 2025-12-16 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
US12503479B2 (en) 2019-04-10 2025-12-23 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
EP2044961B1 (en) 2004-03-02 2013-07-17 Cellectar, Inc. Phospholipid analogues for the treatment of pancreatic, ovarian and colon cancers, melanomas, gliomas, and carcinosarcomas
RU2012100765A (ru) 2009-06-12 2013-07-20 Селлектар, Инк. Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US20050196339A1 (en) * 2004-03-02 2005-09-08 Cellectar, Llc Phospholipid analogs as diapeutic* agents and methods thereof
JP2008545614A (ja) * 2004-12-20 2008-12-18 セレクター、リミテッド ライアビリティ カンパニー 癌の検出および治療のためのリン脂質エーテル類似体
WO2009005509A1 (en) * 2006-08-15 2009-01-08 Cellectar, Inc. Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925649A (en) * 1987-06-12 1990-05-15 The University Of Michigan Radioiodinated diacylglycerol analogues and methods of use
US5347030A (en) * 1987-10-23 1994-09-13 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues and methods of using same
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5626654A (en) * 1995-12-05 1997-05-06 Xerox Corporation Ink compositions containing liposomes
US6255519B1 (en) * 1996-12-04 2001-07-03 Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US6503478B2 (en) * 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
US7220539B1 (en) * 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
US7632644B2 (en) * 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
MXPA06011242A (es) * 2004-03-29 2007-01-16 Univ Arizona Glicopeptidos anfipaticos.
EP1773408A2 (en) * 2004-07-08 2007-04-18 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
US20060115426A1 (en) * 2004-08-11 2006-06-01 Weichert Jamey P Methods of detecting breast cancer, brain cancer, and pancreatic cancer
US7041859B1 (en) * 2004-09-09 2006-05-09 University Of Tennessee Research Foundation Method for halogenating or radiohalogenating a chemical compound
US7893286B2 (en) * 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
RU2012100765A (ru) * 2009-06-12 2013-07-20 Селлектар, Инк. Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток
WO2011031911A1 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Deuterated alkyl phospholipid compounds, compositions, and methods of use
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US20050196339A1 (en) * 2004-03-02 2005-09-08 Cellectar, Llc Phospholipid analogs as diapeutic* agents and methods thereof
JP2008545614A (ja) * 2004-12-20 2008-12-18 セレクター、リミテッド ライアビリティ カンパニー 癌の検出および治療のためのリン脂質エーテル類似体
WO2009005509A1 (en) * 2006-08-15 2009-01-08 Cellectar, Inc. Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535608A (ja) * 2014-11-17 2017-11-30 セレクター・バイオサイエンシズ・インコーポレイテッド 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
US11439709B2 (en) 2014-11-17 2022-09-13 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
US12503479B2 (en) 2019-04-10 2025-12-23 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
US12496346B2 (en) 2019-10-10 2025-12-16 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Also Published As

Publication number Publication date
US20110064661A1 (en) 2011-03-17
US20120156133A1 (en) 2012-06-21
WO2011031919A3 (en) 2014-03-27
RU2012114146A (ru) 2013-10-20
WO2011031919A2 (en) 2011-03-17
EP2475400A2 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
EP3229810B1 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
JP2013504590A (ja) 非放射性リン脂質化合物、組成物、及び使用方法
JP6674586B2 (ja) 血液脳関門通過能を有する置換キナゾリン化合物
KR20180132939A (ko) 암 치료를 위한 조합 요법
EP4086250B1 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CN107108632B (zh) 作为激酶调节剂的氘化的三唑并哒嗪
JP2025087716A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
EP3212650B1 (en) Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
JP2019196380A (ja) Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物
EP3414242A1 (en) Cellular signalling inhibitors, their formulations and methods thereof
CN112851647B (zh) 布雷菲德菌素a衍生物及其制备方法和用途
US20250064824A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
JP2023509191A (ja) 癌を治療するための組み合わせ療法
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
US20160296556A1 (en) Inhibitors of ercc1-xpf and methods of using the same
WO2022051616A1 (en) Cdk targeted heterobifunctional small molecule proteolysis targeting chimeras
US12285412B1 (en) Organoselenium benzimidazole compounds for treating cancer
US12152008B2 (en) Cyclopentaimidazolones for the treatment of cancer
JP6243844B2 (ja) トロンビン受容体アンタゴニストを有効成分とする肺高血圧症の予防治療剤
HK1240924B (en) A deuterated triazolopyridazine as a kinase modulator
HK1240924A1 (en) A deuterated triazolopyridazine as a kinase modulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721